Galsulfase injection
Products billed under this code include Naglazyme.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Naglazyme.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Naglazyme | BioMarin Pharmaceutical Inc. | 68135-0020-01 | 5 | $2,647.90 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $529.58 | +$3.613 | 1 MG | Galsulfase injection | v1, posted September 17, 2026 |
| 3Q26 | $525.967 | +$12.372 | 1 MG | Galsulfase injection | v1, posted September 15, 2026 |
| 2Q26 | $513.595 | −$0.265 | 1 MG | Galsulfase injection | v1, posted September 15, 2026 |
| 1Q26 | $513.86 | +$5.102 | 1 MG | Galsulfase injection | v1, posted September 15, 2026 |
| 4Q25 | $508.758 | +$3.253 | 1 MG | Galsulfase injection | v1, posted September 8, 2026 |
| 3Q25 | $505.505 | +$20.628 | 1 MG | Galsulfase injection | v1, posted March 10, 2026 |
| 2Q25 | $484.877 | −$0.045 | 1 MG | Galsulfase injection | v1, posted March 10, 2026 |
| 1Q25 | $484.922 | +$0.17 | 1 MG | Galsulfase injection | v1, posted December 19, 2025 |
| 4Q24 | $484.752 | +$9.078 | 1 MG | Galsulfase injection | v1, posted June 11, 2025 |
| 3Q24 | $475.674 | +$8.759 | 1 MG | Galsulfase injection | v1, posted June 11, 2025 |
| 2Q24 | $466.915 | +$3.923 | 1 MG | Galsulfase injection | v1, posted March 11, 2025 |
| 1Q24 | $462.992 | −$0.051 | 1 MG | Galsulfase injection | v1, posted December 19, 2024 |
| 4Q23 | $463.043 | +$1.124 | 1 MG | Galsulfase injection | v1, posted October 10, 2024 |
| 3Q23 | $461.919 | +$29.019 | 1 MG | Galsulfase injection | v1, posted June 5, 2024 |
| 2Q23 | $432.90 | +$0.101 | 1 MG | Galsulfase injection | v1, posted February 23, 2024 |
| 1Q23 | $432.799 | +$0.087 | 1 MG | Galsulfase injection | v1, posted December 6, 2023 |
| 4Q22 | $432.712 | +$0.281 | 1 MG | Galsulfase injection | v1, posted June 22, 2023 |
| 3Q22 | $432.431 | +$20.509 | 1 MG | Galsulfase injection | v1, posted June 9, 2023 |
| 2Q22 | $411.922 | +$0.009 | 1 MG | Galsulfase injection | v1, posted December 14, 2022 |
| 1Q22 | $411.913 | −$0.009 | 1 MG | Galsulfase injection | v1, posted June 8, 2022 |
| 4Q21 | $411.922 | +$0.383 | 1 MG | Galsulfase injection | v1, posted June 2, 2022 |
| 3Q21 | $411.539 | +$7.552 | 1 MG | Galsulfase injection | v1, posted June 2, 2022 |
| 2Q21 | $403.987 | −$0.085 | 1 MG | Galsulfase injection | v1, posted March 1, 2022 |
| 1Q21 | $404.072 | – | 1 MG | Galsulfase injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.